Article info

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Authors

  1. Correspondence to Dr Christina Charles-Schoeman, Division of Rheumatology, Department of Medicine, University of California, Los Angeles, California, USA; ccharles{at}mednet.ucla.edu
View Full Text

Citation

Charles-Schoeman C, Buch MH, Dougados M, et al
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Publication history

  • Received January 28, 2022
  • Accepted August 11, 2022
  • First published September 22, 2022.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.